These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Fatal outcomes among patients on maintenance haemodialysis in sub-Saharan Africa: a 10-year audit from the Douala General Hospital in Cameroon. Halle MP; Ashuntantang G; Kaze FF; Takongue C; Kengne AP BMC Nephrol; 2016 Nov; 17(1):165. PubMed ID: 27809790 [TBL] [Abstract][Full Text] [Related]
26. The kidney and cardiovascular outcome trials. Bloomgarden Z J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006 [TBL] [Abstract][Full Text] [Related]
27. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ; Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900 [TBL] [Abstract][Full Text] [Related]
28. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G; Maggioni AP Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394 [TBL] [Abstract][Full Text] [Related]
29. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention. Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial. Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473 [TBL] [Abstract][Full Text] [Related]
31. Penultimate pulse wave velocity, better than baseline pulse wave velocity, predicted mortality in Italian ESRD cohort study - a case for daily hemodialysis for ESRD patients with accelerated pulse wave velocity changes. Onuigbo M; Onuigbo N; Bellasi A; Russo D; Di Iorio BR G Ital Nefrol; 2013; 30(2):. PubMed ID: 23832464 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of stress myocardial perfusion imaging using adenosine triphosphate at the beginning of haemodialysis treatment in patients with end-stage renal disease. Hase H; Joki N; Ishikawa H; Fukuda H; Imamura Y; Saijyo T; Tanaka Y; Takahashi Y; Inishi Y; Nakamura M; Moroi M Nephrol Dial Transplant; 2004 May; 19(5):1161-7. PubMed ID: 14993503 [TBL] [Abstract][Full Text] [Related]
33. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels. Carter NJ Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831 [TBL] [Abstract][Full Text] [Related]
35. Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. Sharma S; Farrington K; Kozarski R; Christopoulos C; Niespialowska-Steuden M; Moffat D; Gorog DA Eur Heart J; 2013 Feb; 34(5):354-63. PubMed ID: 23048192 [TBL] [Abstract][Full Text] [Related]
36. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Caluwé R; Pyfferoen L; De Boeck K; De Vriese AS Clin Kidney J; 2016 Apr; 9(2):273-9. PubMed ID: 26985380 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of statins in patients with end-stage renal disease. Nemerovski CW; Lekura J; Cefaretti M; Mehta PT; Moore CL Ann Pharmacother; 2013 Oct; 47(10):1321-9. PubMed ID: 24259696 [TBL] [Abstract][Full Text] [Related]
38. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease. Sud M; Tangri N; Pintilie M; Levey AS; Naimark D Circulation; 2014 Aug; 130(6):458-65. PubMed ID: 24899688 [TBL] [Abstract][Full Text] [Related]
39. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582 [TBL] [Abstract][Full Text] [Related]